Vimarsana
Biggest News Aggregation in the World

Invalidation Cases News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Invalidation Cases. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Invalidation Cases Today - Breaking & Trending Today

How does pharmacological action affect the defence of a pharmaceutical compound patent in China? - Vimarsana News

How does pharmacological action affect the defence of a pharmaceutical compound patent in China?

Honghui Hu of Wanhuida Intellectual Property explains that a CNIPA ruling on a patent covering an antidepressant could help to determine the patentability of pharmaceutical compounds

China's CNIPA Top 10 2022 Cases of Patent Reexamination Invalidation - Vimarsana News

China's CNIPA Top 10 2022 Cases of Patent Reexamination Invalidation

The top ten patent reexamination and invalidation cases in 2022 include 8 invalidation cases of invention patents, 1 invalidation case of a utility model patent and 1 invalidation case of a design patent.

Chinese SPC elucidates test for evaluating common knowledge evidence - Vimarsana News

Chinese SPC elucidates test for evaluating common knowledge evidence

Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees

 - Vimarsana News

Polymorphism of a pharmaceutical compound refers to its state of existing in different solid forms that is caused by the fact that the molecules of the compound, though being of the...

The CNIPA offers insight in upholding a compound patent's validity | Managing Intellectual Property - Vimarsana News

The CNIPA offers insight in upholding a compound patent's validity | Managing Intellectual Property

Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees